Addressing increasingly resistant drugs by infectious agents
Drug Target Review
SEPTEMBER 4, 2023
7,9 Dihydrofolate reductase-thymidylate synthase (DHFR) have been successfully exploited for the therapy of bacterial infections and other parasitic diseases such as malaria. He has over two years of experience in research and laboratory work. References: Antunes Luisa (2023). 12(11): e0006980. Nilmar, S. and Anabela, C. Michael, A.
111 
Let's personalize your content